3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11820720-B2
Publication Date
2023-11-21
Expiration Date
Abstract
The invention provides 3-deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same, such as in the treatment of cancer, an immune-related disease, or an inflammatory disease.
Core Innovation
The invention relates to deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-dione derivatives, including related deuterium-enriched compound structures, stereoisomers, solvates, and pharmaceutically acceptable salts. The compounds are defined with Z being H or D, where the abundance of deuterium in Z is at least 30%, and structural definitions include variable substituents and deuterium at specified positions.
The disclosure also describes stereochemical purity, including minimum enantiomeric excess and optical purity, and states that deuteration at the 3-position slows stereocenter racemization. The deuterium-enriched compounds include isolated or purified compounds and mixtures or compositions.
The invention further relates to treating lymphoma by administering to a patient in need thereof a therapeutically effective amount of a deuterium-enriched compound, or a pharmaceutically acceptable salt or solvate thereof. The therapeutic context includes Hodgkin’s lymphoma and specified non-Hodgkin’s lymphoma subtypes, and also references cancer, immune-related/lymphocytic activity disorders, inflammatory diseases, and angiogenesis/cytokine-related disorders.
Claims Coverage
The claim coverage centers on one independent method of treating lymphoma with a deuterium-enriched compound, and dependent refinements add lymphoma subtypes and quantitative stereochemical and isotopic constraints. Six inventive features are identified across the provided claim summaries.
Deuterium-enriched compound for lymphoma treatment
Administering to a patient in need thereof a therapeutically effective amount of a deuterium-enriched compound, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is H or D and the abundance of deuterium in Z is at least 30%.
Hodgkin’s lymphoma treatment
The method of treating lymphoma where the lymphoma is Hodgkin’s lymphoma.
Non-Hodgkin’s lymphoma subtype selection
The method where the non-Hodgkin’s lymphoma is selected from a specified group of particular lymphoma types.
High deuterium abundance threshold
The deuterium-enriched compound has an abundance of deuterium in Z of at least 80%.
Very high deuterium abundance threshold
The deuterium-enriched compound has an abundance of deuterium in Z of at least 90%.
Enantiomeric excess stereochemical constraint
The deuterium-enriched compound, or its pharmaceutically acceptable salt or solvate, has an enantiomeric excess of at least 90%.
Overall, the claim coverage is directed to treating lymphoma by administering a deuterium-enriched compound defined by Z (H or D) with at least 30% deuterium abundance. Dependent claims further narrow the lymphoma types, including Hodgkin’s lymphoma and enumerated non-Hodgkin’s lymphoma subtypes, and add higher deuterium abundance thresholds and a minimum enantiomeric excess of at least 90%.
Stated Advantages
Novelty rationale based on deuterium enrichment greater than natural abundance.
Anti-racemization benefit.
Documented Applications
Treating lymphoma by administering a therapeutically effective amount of a deuterium-enriched compound, or a pharmaceutically acceptable salt or solvate thereof, including Hodgkin’s lymphoma and specified non-Hodgkin’s lymphoma subtypes.
Treating diseases and disorders including cancer, immune-related/lymphocytic activity disorders, inflammatory diseases, and angiogenesis/cytokine-related disorders.
Interested in licensing this patent?